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Abstract
Background: Valproic acid (VPA) is a potent anticonvulsant that inhibits histone deacetylases. Because of this inhibitory
action, we investigated whether VPA would affect chromatin supraorganization, mitotic indices and the frequency of
chromosome abnormalities and cell death in HeLa cells.
Methodology/Principal Findings: Image analysis was performed by scanning microspectrophotometry for cells cultivated
for 24 h, treated with 0.05, 0.5 or 1.0 mM VPA for 1–24 h, and subjected to the Feulgen reaction. TSA-treated cells were
used as a predictable positive control. DNA fragmentation was investigated with the TUNEL assay. Chromatin
decondensation was demonstrated under TSA and all VPA treatments, but no changes in chromosome abnormalities,
mitotic indices or morphologically identified cell death were found with the VPA treatment conditions mentioned above,
although decreased mitotic indices were detected under higher VPA concentration and longer exposure time. The
frequency of DNA fragmentation identified with the TUNEL assay in HeLa cells increased after a 24-h VPA treatment,
although this fragmentation occurred much earlier after treatment with TSA.
Conclusions/Significance: The inhibition of histone deacetylases by VPA induces chromatin remodeling in HeLa cells, which
suggests an association to altered gene expression. Under VPA doses close to the therapeutic antiepileptic plasma range no
changes in cell proliferation or chromosome abnormalities are elicited. The DNA fragmentation results indicate that a longer
exposure to VPA or a higher VPA concentration is required for the induction of cell death.
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Introduction
Valproic acid (VPA) is a drug widely prescribed for the
treatment of seizure disorders, including epilepsy, episodes related
to bipolar disorder and migraine headaches [1–3]. In addition to
inhibiting the transamination of the neurotransmitter GABA and
blocking the voltage-gated sodium channels and T-type calcium
channels [4] within a therapeutic antiepileptic plasma range
(0.3 mM-0.7 mM), VPA is a potent inhibitor of class I histone
deacetylases (HDACs) in several cell types [1,5–12]. Recent
findings have supported the proposal of a dynamic interplay
between histone acetylation, histone methylation and DNA
demethylation in response to VPA treatment in certain cell
systems [7,13–15].
While there is only a minute amount of acetylated histones in
HeLa cells, treatment of these cells with VPA at a concentration as
low as 0.25 mM increases the amount of acetylated histone H4,
and treatment at a concentration of 2 mM induces its massive
acetylation [5]. Accumulation of acetylated histone H4 was
observed as early as 1 h after the addition of 0.5 or 1.0 mM
VPA to the culture medium [6]. Maximum histone H4 acetylation
in HeLa cells appears nearly 12-16 h after VPA addition [6].
Acetylation of histone H3 also significantly increases in HeLa and
L929 cells after VPA treatment [16,17].
The epigenetic effect of hyperacetylation of histones by VPA
activates transcription from diverse promoters [1] and has been
considered promising for the control of certain cell malignancies
[5,8,18–21]. On the other hand, the hyperacetylation of histones
induced by a class I-specific HDAC inhibitor (HDACi) like VPA
or by a pan-HDACi such as trichostatin A (TSA) [11] has been
considered totally or at least partly responsible for the similar
teratogenic side-effects in vertebrate embryos [1,17,22].
Changes in chromatin supraorganization and nuclear architec-
ture in HeLa cells after treatment with TSA have been described
as a result of the enhanced acetylation of nucleosome core histones
[23,24]. Exposure to VPA, in addition to histone acetylation, has
also been shown to induce the depletion of proteins that maintain
chromatin structure in breast MCF-7 cancer cells thus leading to
the potentiation of DNA-damaging agents [7]. Treatment of
prostate cancer cells in vitro and in vivo with VPA has been reported
to result in dose- and time-dependent changes in nuclear structure
[8].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29144HDACis have also been implicated in the cell cycle arrest and
apoptosis intrinsic and extrinsic pathways, inducing the expression
of genes encoding cell death receptors and their cognate ligands or
mediating the repression of genes that encode inhibitors of these
pathways [18,25–33]. In addition to eliciting apoptotic pathways,
HDACis have been reported to be involved with the induction of
autophagic cell death, mitotic cell death and senescence in various
transformed cell lines [27,33]. Acetylation of non-histone proteins
by HDACis may account for their reported antitumor responses or
synergistic effects when HDACis are combined with pro-apoptotic
agents [26,27,31].
Here, we investigated whether VPA, as a consequence of its
epigenetic action, would affect chromatin supraorganization in
HeLa cells similarly to TSA in these cells [23] or to VPA in
prostate cancer cells [8] or even in breast cancer cells [7], using an
appropriate image analysis method. In addition, as cell prolifer-
ation and cell death may also be affected by VPA, Feulgen-DNA
C classes, cell death morphological aspects and DNA fragmenta-
tion were investigated in parallel with chromatin texture analysis
and with the frequency of chromosome abnormalities.
Results
Image Analysis
False-color images suggestive of chromatin unpackaging could
be observed especially with shorter (1-2 h) VPA treatment in the
Feulgen-stained nuclei. Nuclear areas covered by condensed
chromatin packaging (revealed as green points), which were
abundant in untreated controls (Fig. 1 A), appeared reduced in
VPA-treated cells (Fig. 1 B). Scatter diagrams in which nuclear
relative areas covered with condensed chromatin (Sc %) were
related to the level of textural contrast between condensed and
non-condensed chromatin (AAR), were obtained for the nuclei
analyzed by scanning microspectrophotometry. These scatter plots
were compared with the schematic model by Vidal [34] and Mello
et al. [35], which allows for the discrimination of the position in
this diagram of points corresponding to specific nuclear pheno-
typic images (Fig. 2 A). When HeLa cells were treated with
100 ng/mL TSA as a positive control to induce chromatin
loosening, decreased Sc% values with increasing AAR values were
demonstrated in the scatter plot representation (Fig. 2 B) or after
statistical comparison (Table 1).
Similar to the data obtained for TSA-treated cells, the results
obtained for the cells treated with 0.05, 0.5 or 1.0 mM VPA for 1,
2, 4 or 24 h showed decreasing values of Sc % and generally
increased values of AAR in comparison with the respective
untreated controls (Fig. 3, 4, 5; Tables 2, 3, 4).
Figure 1. False-colored images of Feulgen-stained HeLa cells.
Condensed chromatin packaging revealed as green points is less
frequent in VPA-treated cells (B) in comparison with untreated controls
(A). Scale bar, 25 mm.
doi:10.1371/journal.pone.0029144.g001
Figure 2. Scatter diagrams representing positioning of nuclei
with different phenotypic images in Feulgen-stained cells.
These diagrams relate Sc% (relative condensed chromatin area) and
AAR (the level of textural contrast between condensed and non-
condensed chromatin). A. Schematic model diagram modified from
Vidal (1984) and Mello et al. (2009). B. HeLa cells treated with 100 ng/
mL TSA (yellow), in comparison to untreated controls (black).
doi:10.1371/journal.pone.0029144.g002
Table 1. Condensed chromatin area and chromatin textural
contrast in HeLa cells treated with 100 ng/mL TSA for 24 h.
Treatment Sc % AAR
X S Md X S Md
Untreated control 58.77 13.12 60.05
a 1.33 0.10 1.32
a
TSA 37.74 18.20 40.86
b 1.47 0.12 1.45
b
a,b, The median values of the TSA and control groups differ significantly from
each other at the P0.05 level (Mann-Whitney test); AAR, average absorption
ratio; Md, median: S, standard deviation; Sc %, relative condensed chromatin
area; TSA, trichostatin A; X, arithmetic mean; n, 100
doi:10.1371/journal.pone.0029144.t001
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Indeed, the significant decrease in AT values in the VPA-treated
cells (Table 5) was due to a smaller frequency of nuclei with larger
Feulgen-DNA amounts in comparison to respective controls (Fig.
S1, S2, S3, and S4). An increase in the nuclear areas after 1- and
2-h VPA treatments was demonstrated statistically by the Mann-
Whitney test (Table 5); however, after longer exposure times, this
increase was masked when considering the arithmetic means and
medians of the ST values, most likely because the frequency of
nuclei with the highest Feulgen-DNA values under these
conditions diminished (Fig. S1, S2, S3, and S4).
In most cases, . 50% of the nuclei were found to present a
Feulgen-DNA content in the ‘‘,2 C’’ Feulgen-DNA degree class
(G1 phase) irrespective of control or VPA treatments (Figs. S1, S2,
S3, and S4). The ‘‘,2 C’’ degree class was named here as the class
containing the smallest values presented by control cells after 1 h
in growing conditions, considering that HeLa cells constitute a
heteroploid cell strain with aneuploidy characteristics [36], and
was also comparable to the Feulgen-DNA value distribution
presented by human lymphocytes (Fig. S1). A decrease in the
frequency of nuclei in the next doubling DNA C classes was
generally induced by VPA as early as 1 h following treatment and
at a drug dose as low as 0.05 mM. Conversely, an increase in the
frequency of nuclei with Feulgen-DNA values , ‘‘,2C’’ occurred
with the VPA treatments.
All of these data indicate that chromatin decondensation
occurred under the treatment conditions studied here.
Mitotic Indices, Mitotic Abnormalities, Micronucleation
and Cell Death Ratios
No statistically significant changes in the mitotic index were
observed for the 0.05, 0.5 or 1.0 mM VPA treatments for 1, 2, 4
and 24 h (Table S1). However, when the cells were treated for
48 h at a VPA concentration that is considerably higher (5.0 mM)
than the therapeutic range [5,6], the mitotic indices significantly
decreased (Table S1).
Abnormal mitoses were observed under all experimental
conditions analyzed. However, no change in the frequency of
mitotic abnormalities, micronuclei and giant nuclei was intro-
duced by the VPA treatment, except for a decrease in the
frequency of giant nuclei after treatment with 5.0 mM VPA for
48 h (Table S1). The high frequency of abnormal mitosis in the
preparations treated with 5.0 mM VPA for 48 h resulted from the
reduced number of mitoses under this condition and their
generally abnormal characteristics of the cells (Table S1).
Examples of mitotic abnormalities, such as tripolar spindles,
chromosome bridges, lagging chromosomes, a micronucleated cell
and a giant nucleus, are shown in Figures 6 D-I.
Cell death morphologies associated with apoptosis and cell
death preceded by multinucleation (Fig. 6 A–C) were also
observed in all cell preparations examined. The apoptotic ratios
and the frequency of cell death preceded by multinucleation based
on cell morphological aspects detected in the Feulgen-stained
preparations were not affected by VPA treatments in comparison
with untreated controls (Table S1).
Figure 3. Scatter diagrams of Sc% vs. AAR for Feulgen-stained HeLa cells. The nuclei from cells treated with 0.05 mM VPA for 1 (A), 2 (B), 4
(C), or 24 h (D) are represented in blue in comparison with untreated controls, which are represented in black. n, 200.
doi:10.1371/journal.pone.0029144.g003
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No labeling was found in the absence of TdT (negative control)
(Fig. 7 A, B), indicating that the positive immunocytochemical
response was not caused by endogenous cell peroxidases. In
addition, there was a very strong positive response in cells treated
with DNase (positive control) (Fig. 7 C). Variations in the intensity
of the positive response to the TUNEL assay (weak, moderate and
strong) were detected in HeLa cells in the absence or presence of
TSA or VPA treatment (Fig. 7 D–I, G, H; Table 6). DNA
fragmentation was also detected in cells undergoing cell death
preceded by multinucleation (Fig. 7 F).
While the positive response in the TUNEL assay increased with
all doses of the 4 and 24-h TSA treatment used, only the 24 h
VPA treatments induced a significant increase in this response
(Table 6).
Discussion
The results indicate an induction of chromatin decondensation
in VPA-treated HeLa cells as assessed by image analysis
procedures. Image analysis cytometry similar to that employed
here has allowed the identification of chromatin remodeling in
several other cell types under different physiological or patholog-
ical conditions [23,34,35,37–41]. Chromatin decondensation in
HeLa cells was not a VPA-selective or direct effect, as it also
occurred by HDAC inhibition in VPA-treated MCF-7 cells [7]
and in TSA-treated HeLa cells [23,24]. Chromatin decondensa-
tion in HeLa cells was verified at VPA exposure times as short as
1 h and at drug doses as low as 0. 25 mM. VPA-induced
acetylation of histones H3 and H4 have been verified under these
mild experimental conditions in MCF-7 cells [7].
The observed textural changes in the chromatin appeared
under conditions in which several reports demonstrated that
HDAC activity decreased and histone acetylation increased under
treatment with VPA and TSA in HeLa cells [6,16,23].
Consequently, we found it unnecessary to repeat the previously
reported biochemical experiment on HDAC activity and Western
blot analysis in the present study. In addition, current studies in
our laboratory involving image analysis of NIH 3T3 cells treated
with VPA and TSA and a previous study on the human glioma
NG97 cells, which is a cell line described to derive from a grade III
astrocytoma [42], indicate similar textural changes in chromatin.
The results for the NIH 3T3 cells are accompanied by increased
histone H3 and H4 acetylation (demonstrated by Western blotting)
and decreased HDAC activity.
It is well known that histone modification, specifically, histone
acetylation and deacetylation, is a key factor in the regulation of
gene expression, and that dynamic changes in gene expression can
affect chromatin structure and its interaction with regulatory
factors [7]. HDACis like VPA induce gene deregulation, leading,
for instance, to the expression of specific genes [10,43,44] and to
the induction of teratogenicity [22]. Because VPA elicits
chromatin decondensation in HeLa cells, it most likely affects
the expression of at least some of their genes. Indeed, treatment of
HeLa cells with 3.0 mM VPA for 24 h, a condition that
approaches that required for the induction of H4 hyperacetylation,
has revealed deregulation of 6% of HeLa cell genes (1625), as
assessed by DNA chip analyses [12]. In this case, more genes are
Figure 4. Scatter diagrams of Sc% vs. AAR for Feulgen-stained HeLa cells. The nuclei from cells treated with 0.5 mM VPA for 1 (A), 2 (B), 4
(C), or 24 h (D) are represented in red in comparison with untreated controls, which are represented in black. n, 200.
doi:10.1371/journal.pone.0029144.g004
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genes are deregulated by VPA than the knockdown of HDAC1, -2
and -3 [12]. Genes that were up-regulated more than 2-fold
compared to those in the untreated or scrambled control groups
were found to be related to the cell cycle (e.g., p21, HRAS-like
suppressor 3 and cyclin D2), cell signaling (RAS guanyl releasing
protein 2, transforming growth factor-alpha and glycoprotein
hormones) and other functions (pyruvate dehydrogenase kinase 4
and ATPase class V, type IOD) [12]. Down-regulated genes were
found to be related to importin b, Fas apoptotic inhibitory
Figure 5. Scatter diagrams of Sc% vs. AAR for Feulgen-stained HeLa cells. The nuclei from cells treated with 1.0 mM VPA for 1 (A), 2 (B), 4
(C), or 24 h (D) are represented in green in comparison with untreated controls, which are represented in black. n, 200.
doi:10.1371/journal.pone.0029144.g005
Table 2. Condensed chromatin area and chromatin textural
contrast in 0.05 mM VPA- treated HeLa cells
Treatment Sc% AAR
time (h) Drug X S Md X S Md
1 Untreated control 69.17 10.13 70.77
a 1.27 0.09 1.26
a
VPA 36.33 25.04 38.22
b 1.40 0.17 1.37
b
2 Untreated control 68.53 14.52 70.65
a 1.25 0.08 1.24
a
VPA 37.29 22.07 36.85
b 1.44 0.16 1.42
b
4 Untreated control 60.15 13.17 60.86
a 1.36 0.14 1.35
a
VPA 33.43 20.81 31.25
b 1.40 0.15 1.38
b
24 Untreated control 57.75 14.84 59.91
a 1.35 0.14 1.32
a
VPA 38.76 18.96 40.84
b 1.40 0.11 1.39
b
a,b, The median values of the VPA group and the respective control for each
treatment time differ significantly from each other at the P 0.05 level (Mann-
Whitney test); AAR, average absorption ratio; Md, median; S, standard
deviation; Sc %, relative condensed chromatin area; VPA, valproic acid; X,
arithmetic mean; n, 200
doi:10.1371/journal.pone.0029144.t002
Table 3. Condensed chromatin area and chromatin textural
contrast in 0.5 mM VPA- treated HeLa cells.
Treatment Sc% AAR
time (h) Drug X S Md X S Md
1 Untreated control 69.17 10.13 70.77
a 1.27 0.09 1.26
a
VPA 41.30 21.91 41.76
b 1.39 0.16 1.36
b
2 Untreated control 68.53 14.52 70.65
a 1.25 0.08 1.24
a
VPA 30.51 20.73 31.11
b 1.44 0.15 1.43
b
4 Untreated control 60.15 13.17 60.86
a 1.36 0.14 1.35
a
VPA 49.52 21.42 56.41
b 1.39 0.15 1.38
a
24 Untreated control 57.75 14.84 59.91
a 1.35 0.14 1.32
a
VPA 42.31 22.42 47.41
b 1.38 0.15 1.34
a
a,b, The median values of the VPA groups and their respective control for each
treatment time differ significantly from each at the P 0.05 level (Mann-Whitney
test); AAR, average absorption ratio; Md, median; S, standard deviation; Sc %,
relative condensed chromatin area; VPA, valproic acid; X, arithmetic mean; n,
200
doi:10.1371/journal.pone.0029144.t003
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TSA, microarray analysis has revealed that 726 genes are up-
regulated (particularly those involved in epileptogenesis), whereas
577 genes are down-regulated (particularly those responsible for
the development of GABAergic inhibitory neurons) [45]. In this
case, the acetylation of histones H3 and H4 is increased only in the
promoters of the up-regulated genes [45].
It is worth mentioning that in the human breast cancer cell line
MCF-7, the chromatin decondensation that is promoted in
response to VPA-induced HDAC inhibition is accompanied by
an increased sensitivity of DNA to nucleases and an increased
association of DNA with intercalating agents that have been
assumed to be modulated by the depletion of non-histone proteins
involved in the maintenance of chromatin structure (SMC) [7]. A
decrease in the expression of genes encoding the SMC proteins,
SMC-associated proteins, DNA methyltransferase 1 and HP1
(heterochromatin protein 1), as determined by microarray analysis,
has been ascribed to HDAC inhibition, rather than to a direct
VPA effect [7]. In the present study, the role of depletion of such
proteins on chromatin decondensation in HeLa cells cannot be
ruled out.
In addition to histone hyperacetylation, DNA demethylation of
specific genes is also triggered by VPA in HEK293 cells [13,14],
but not in FXS (fragile X syndrome) lymphoblastoid cell lines in
which the FMR1 gene is silenced by DNA methylation [46] or in
mouse embryos [47]. It should be emphasized that in contrast to
histone acetylation, the induction of DNA demethylation by VPA
can cause long-term consequences for the integrity of gene
expression programming by reversing stable DNA methylation
patterns in nondividing cells [13,14]. HDAC inhibition by VPA
and TSA has also been recently reported to induce histone
methylation in rat cortical neurons and astrocytes in which these
drugs up-regulate overall and gene-specific H3K4 di- and
trimethylation [15] and to increase H3K4 methylation but
decrease H3K9 methylation in mouse embryos [47]. There is no
record of HDACi-promoted histone methylation or DNA
demethylation in HeLa cells. Consequently, chromatin remodeling
in HeLa cells, as found in this study, cannot be discussed in these
terms. Certainly, further investigation is required, including image
analysis of cells first treated with VPA and subsequently cultured
in the absence of this drug, comparison of these results with data
obtained on cells treated with 5-azacytidine and biochemical
studies on this matter.
The increase with the VPA treatments in the number of nuclei
containing subdiploid class Feulgen-DNA amounts, which is not
accompanied by an increase in DNA fragmentation or in
frequency of cell death images, probably indicates an increased
apurinic acid solubilization during the acid hydrolysis phase of the
Feulgen reaction. This increase in apurinic acid solubilization
could be due to a decrease in resistance of the DNA to the
hydrolytic process [48] because of the chromatin unraveling
promoted by the HDACi. Indeed, VPA-induced chromatin
decondensation in MCF-7 cells has been associated with an
increased sensitivity of the DNA to nucleases and with an
increased access of the DNA to intercalating agents [7]. Given
these findings, the apparent decrease in the frequency of nuclei
with the largest Feulgen-DNA values with the 0.05–1.0 mM VPA
treatment for 1, 2, 4 and 24 h does not mean decreased cell
proliferation, which is supported by the fact that mitotic indices
are unaffected under these experimental conditions.
The significant decrease in mitotic indices revealed with the
5.0 mM VPA treatment for 48 h indicates that relatively long
periods of treatment and/or high doses of this drug are required
for an effect on HeLa cell proliferation, which confirms previous
data for this cell line [16] and is also consistent with a report for
leukemic cells [33]. Conversely, even under this antiproliferative
condition, no effect was verified on the frequency of cell death, as
determined by morphology in Feulgen-stained preparations,
which was used for the calculation of cell death ratios in VPA-
Table 4. Condensed chromatin area and chromatin textural
contrast in 1.0 mM VPA- treated HeLa cells.
Treatment Sc% AAR
time
(h) Drug X S Md X S Md
1 Untreated
control
69.17 10.13 70.77
a 1.27 0.09 1.26
a
VPA 44.53 22.93 45.57
b 1.36 0.13 1.34
b
2 Untreated
control
68.53 14.52 70.65
a 1.25 0.08 1.24
a
VPA 23.96 18.88 20.67
b 1.50 0.16 1.48
b
4 Untreated
control
60.15 13.17 60.86
a 1.36 0.14 1.35
a
VPA 53.20 17.86 56.93
b 1.34 0.12 1.32
a
24 Untreated
control
57.75 14.84 59.91
a 1.35 0.14 1.32
a
VPA 34.18 22.18 35.55
b 1.44 0.15 1.42
b
a,b, The median values of the VPA groups and their respective control for each
treatment time differ significantly at the P 0.05 level (Mann-Whitney test); AAR,
average absorption ratio; Md, median; S, standard deviation; Sc %, relative
condensed chromatin area; VPA, valproic acid; X, arithmetic mean; n, 200
doi:10.1371/journal.pone.0029144.t004
Table 5. DNA content and nuclear area in VPA-treated HeLa
cells
Treatment AT (arbitrary units) ST (mm
2)
time (h) VPA (mM) X S Md X S Md
1 zero 123.91 55.28 100.25
a 209.95 71.54 191.00
a
0.05 87.93 33.91 74.80
b 242.21 61.76 231.25
b
0.5 88.45 34.01 79.32
b 236.06 81.05 222.88
c
1.0 95.76 46.93 79.43
b 237.78 84.88 216.25
c
2 zero 138.86 62.13 116.72
a 251.97 88.40 237.50
a
0.05 108.73 46.60 98.00
b 311.12 110.77 296.88
b
0.5 99.77 41.56 95.56
b 301.52 108.03 295.13
b
1.0 60.30 21.85 60.66
c 199.95 57.02 193.00
c
4 zero 143.62 85.52 115.56
a 287.55 102.09 261.50
a
0.05 88.20 31.52 82.01
b 262.89 95.41 242.88
b
0.5 109.32 52.79 96.44
c 262.32 77.61 241.50
c
1.0 100.82 31.17 93.18
c 248.93 77.17 236.00
b
24 zero 138.97 72.65 112.06
a 306.20 103.73 288.50
a
0.05 93.43 41.31 90.86
b 263.90 104.72 261.00
b
0.5 98.31 40.05 94.42
b 270.31 87.50 253.75
b
1.0 100.03 42.13 92.73
b 292.64 90.93 277.75
a
b, c, The median values of the VPA groups differ significantly from each other
and from their respective control (zero,
a)a tt h eP0.05 level (Mann-Whitney test)
AT, nuclear DNA content; Md, median; S, standard deviation; ST, nuclear area;
VPA, valproic acid; n, 200 cells per experimental condition.
doi:10.1371/journal.pone.0029144.t005
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a positive response in the TUNEL assay, increased after a 24-h
treatment with VPA and a $ 4-h treatment with TSA. This
finding indicates that a longer VPA exposure time and/or a higher
drug concentration is required for the DNA fragmentation
pathways to proceed to chromatin condensation and the release
of apoptotic bodies. As regards the TSA action, the much earlier
induction of DNA fragmentation as found in the present study is in
agreement with reports for apoptosis reported for HeLa and other
tumor cell lines [28–30,32,49]. Additionally, DNA fragmentation
could be facilitated by chromatin decondensation promoted by the
HDAC inhibitors.
Materials and Methods
Cell Culture
HeLa cells at passage 176 were grown in Dulbecco’s modified
essential medium (DMEM) (SigmaH, St. Louis, USA) containing
10% fetal calf serum (FCS) (CultilabH, Campinas, Brazil) and
50 mg/mL of garamicin (SigmaH) and incubated at 37uCi na5 %
CO2 atmosphere. HeLa cells were originally acquired from the
Instituto Adolfo Lutz (Sa ˜o Paulo, Brazil) at passage 126 which by
turn had been commercially acquired from ATCC CCL-2
(Manassas, USA). The cells were seeded into 24-well plates
(TPP, Trasadingen, Switzerland) containing round glass coverslips
at a concentration of 5610
4 cells/mL in complete medium for
24 h. Next they were treated with VPA (SigmaH) dissolved in PBS
and diluted in the DMEM medium supplemented with 1% FCS at
doses of 0.05, 0.5 or 1.0 mM for varying times (1, 2, 4 and 24 h).
Only to evaluate mitotic indices, nuclear abnormalities and cell
death ratios, cells treated with VPA at the dose of 5.0 mM for 48 h
was also analyzed. VPA at concentrations of 0.3–1.0 mM acts as a
potent inhibitor of HDAC activity [5]. TSA (SigmaH) dissolved in
DMSO (Labsynth, Diadema, Brazil) and diluted in medium
containing 1% FCS at the dose of 100 ng/mL for 24 h (image
analysis) and at the doses of 10, 20 and 100 ng/mL for 4 and 24 h
(TUNEL assay) was used as a positive control of pan-HDACI
activity [23,24]. Controls in the absence of the drugs were also
used.
Cell Fixation and DNA Topochemistry
The cells adhered to round glass coverslips were fixed in a
mixture of absolute ethanol-glacial acetic acid (3:1, v/v) for 1 min,
rinsed in 70% ethanol and air dried at room temperature. Another
set of cell preparations was fixed in 4% paraformaldehyde for
15 min, rinsed in phosphate saline buffer and air dried.
The cells fixed in acetic ethanol were used for DNA
topochemistry and image analysis, and for the establishment of
mitotic indices and apoptotic ratios. They were subjected to the
Feulgen reaction with hydrolysis carried out in 4 M HCl for
60 min at 25uC. The hydrolyzed material was treated with Schiff
reagent for 40 min, rinsed three times (5 min each) in sulfurous
water and once in distilled water, air dried, cleared in xylene and
mounted in Canada balsam (nD=1.54). Acetic ethanol-fixed
Figure 6. Cell death aspects, mitotic abnormalities and micronuclei in Feulgen-stained HeLa cells. Apoptosis (A, B – arrows), cell death
preceded by multinucleation (C), a giant nucleus (D – arrow), chromosome bridges (E, F), a micronucleus (F – arrow), lagging chromosomes (G, H –
arrows), and a tripolar spindle (I) are observed. Scale bar, 25 mm.
doi:10.1371/journal.pone.0029144.g006
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reaction under hydrolysis conditions which enabled maximal
depurination (4 M HCl for 90 min at 25uC). These cells were used
as a control for 2 C ploidy.
The cells fixed in paraformaldehyde were used for the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick 39-end
DNA labeling (TUNEL) assay.
Scanning Microspectrophotometry Image Analysis
Images of the Feulgen-stained nuclei were obtained with a
Zeiss automatic scanning microspectrophotometer (Carl Zeiss,
Oberkochen, Germany) interfaced to a personal computer. The
operating conditions used were as follows: Planapo objective 63/
0.90; optovar 2.0; measuring diaphragm diameter, 0.25 mm;
field diaphragm diameter, 0.20 mm; LD-Epiplan 16/0.30
condenser; scanning spot of 0.5 mm x 0.5 mm; halogen 100-W/
12-V lamp; stabilized electronic power supply, Zeiss light
modulator; l=565 nm obtained with a Schott monochromator
filter ruler; R-928 photomultiplier; and a Pentium II microcom-
puter. Grid points (individual measuring points) showing
absorbances no higher than 0.020 were considered to be
background and were automatically removed from the nuclear
image. The cutoff point of 0.100 was selected to evaluate the
areas covered by condensed chromatin in HeLa cells after a
preliminary test done for untreated controls. Two hundred nuclei
were chosen at random and measured individually for each
experimental condition.
The image analysis parameters pertinent to this investigation
were as follows: AT, total integrated absorbance = nuclear
Feulgen-DNA values or IOD (integrated optical density) in
arbitrary units; AC, integrated absorbance over the preselected
cutoff (’’condensed’’ chromatin Feulgen-DNA values); AC %,
‘‘condensed’’ chromatin Feulgen-DNA values relative to the
nuclear (whole chromatin) Feulgen-DNA values; ST, nuclear
absorbing area in mm
2;S C, area in mm
2 covered with stained
chromatin showing absorbance above the selected cutoff point; SC
%, area covered with ‘‘condensed’’ chromatin relative to the
nuclear area; AAR = (AC/SC)/(AT/ST), average absorption ratio,
a dimensionless parameter that expresses how many times the
average absorbance of the ‘‘condensed’’ chromatin exceeds that of
the entire nucleus [50]. A scatter diagram relating AAR to SC%
was plotted as previously proposed [34,51]. This diagram allows
for the discrimination of the position of points that correspond to
specific nuclear phenotypes [34,35,51].
Mitotic Abnormalities, Micronucleation, Mitotic Indices
and Cell Death Ratios
The frequency of abnormal metaphases, lagging chromosomes,
chromosome bridging, giant nuclei, micronucleation and mitotic
indices were estimated in Feulgen-stained preparations.
Figure 7. DNA fragmentation revealed in HeLa cells with the TUNEL assay. A, B. Negative control; C. Positive control. D-F. TSA-treated cells
(arrowhead, cell death preceded by multinucleation); G, H. VPA-treated cells. Positive response intensities: strong (D, E), moderate (G, H (arrow)), weak
(F, arrow). Scale bars, 25 mm.
doi:10.1371/journal.pone.0029144.g007
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preceded by multinucleation’’ (denomination recommended in
substitution to mitotic catastrophe) [52] were also evaluated in the
preparations subjected to the Feulgen reaction. Apoptotic cells
were considered here as cells presenting extremely condensed
chromatin or apoptotic bodies. Approximately 2000 cells per
preparation were examined in all cases.
TUNEL Assay
TUNEL analysis was performed following the manufacturer’s
instructions (Roche,M a n n h e i m ,G e r m a n y ) .E n d o g e n o u sp e r -
oxidase was blocked with 3% H2O2 in absolute methanol for
10 min at room temperature. Some preparations were processed
by omitting TdT (negative control) or by including a DNase
treatment before TdT addition (positive control). Counterstain-
ing was performed in a methyl green (Merck, Darmstadt,
Germany) solution. Nuclei with brown-stained spots indicated
TUNEL positive cells. The intensities of positive responses in
the TUNEL assay were visually ranked as weak, moderate or
strong. This classification was supported by a quantitative image
analysis approach, which was performed by defining values of
nuclear relative areas covered by the ‘‘dark’’ brown spots that
resulted from the immunocytochemical assay. Image analysis
was conducted with Kontron KS400 version 3 software and
Zeiss Axiophot 2/Kontron equipment (Oberkochen/Munich,
Germany), using a Neofluar objective 40/0.75, an optovar
factor of 1.4 and a Zeiss AxioCam HRc color video camera.
After the area for the whole nucleus was computed, the
definition of the image area covered by the dark spots was
obtained in this system by fixing the low and high threshold
range levels to 60 and 100 units, respectively. While maintaining
these parameters, nuclei with a strong response in the TUNEL
assay were defined as those that contained dark spots over $
50% of their area. Nuclei with moderate and weak responses
contained dark spots over 5–49% and ,5% of their areas,
respectively. The use of mean gray values as a quantitative
parameter for discrimination of the TUNEL response did not
appear adequate because the reaction observed in this assay was
not found to conform to the Beer-Lambert law. The TUNEL
assay response was determined for 1000 cells under each
experimental condition. Three coverslips for each experimental
condition were examined.
Statistics
Calculations and statistical analyses were performed using
Minitab 12
TM software (State College, PA, USA). Statistical
significance was calculated by the two-sided Student t-test when
the samples showed a normal distribution. The Mann-Whitney
test was performed to assess the statistical significance when the
samples did not show a normal distribution. P,0.05 was considered
the critical level for rejection of the null hypothesis.
Supporting Information
Figure S1 Frequency histograms of Feulgen-DNA val-
ues in HeLa cells treated with VPA for 1 h. n, 200.
Table 6. TUNEL positivity in VPA-treated HeLa cells
Treatment TUNEL positive response (%)
time (h) Drug Concentration Total Strong Moderate Weak
1 VPA zero 0.37
a 0.00
a 0.09
a 0.28
a
0.05 mM 0.90
a 0.00
a 0.00
a 0.90
a
0.5 mM 0.80
a 0.00
a 0.00
a 0.80
a
1.0 mM 1.80
a 0.00
a 0.00
a 1.80
a
2 VPA zero 2.35
a 0.10
a 0.30
a 1.95
a
0.05 mM 3.60
a 0.00
a 0.10
a 3.50
a
0.5 mM 4.40
a 0.00
a 0.60
a 3.80
a
1.0 mM 4.00
a 0.10
a 0.60
a 3.30
a
4 VPA/TSA zero 1.70
a 0.00
a 0.50
a 1.20
a
VPA 0.05 mM 1.80
a 0.00
a 0.10
a 1.70
a
0.5 mM 1.30
a 0.10
a 0.00
a 1.20
a
1.0 mM 8.10
a 3.50
a 1.70
a 2.90
a
TSA 10 ng/mL 30.10
b 12.60
b 9.70
b 7.80
a
20 ng/mL 35.90
b 24.50
b 6.30
b 5.10
a
100 ng/mL 43.90
b 18.95
b 20.00
b 4.95
a
24 VPA/TSA zero 5.90
a 0.30
a 0.40
a 5.20
a
VPA 0.05 mM 14.90
b 0.60
a 1.90
a 12.40
b
0.5 mM 21.50
b 1.10
a 1.20
a 19.20
b
1.0 mM 36.00
b 0.70
a 3.60
a 31.70
b
TSA 10 ng/mL 11.00
a 0.70
a 0.30
a 10.00
a
20 ng/mL 31.40
b 1.20
a 4.60
a 25.60
b
100 ng/mL 60.90
b 7.80
b 13.60
b 39.60
b
b, VPA- or TSA-treated groups differ significantly from their respective controls (zero,
a)a tt h eP0.05 level (Mann-Whitney test); TSA, trichostatin A; VPA, valproic acid; n, 1000 cells per experimental condition.
doi:10.1371/journal.pone.0029144.t006
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Feulgen-DNA.
(TIF)
Figure S2 Frequency histograms of Feulgen-DNA values
in HeLa cells treated with VPA for 2 h. n, 200. For the
reference on human lymphocyte, see Fig. S1.
(TIFF)
Figure S3 Frequency histograms of Feulgen-DNA values
in HeLa cells treated with VPA for 4 h. n, 200. For the
reference on human lymphocyte, see Fig. S1.
(TIFF)
Figure S4 Frequency histograms of Feulgen-DNA values
in HeLa cells treated with VPA for 24 h. n, 200. For the
reference on human lymphocyte, see Fig. S1.
(TIFF)
Table S1 Mitotic index, nuclear abnormalities and cell
death ratios in Feulgen-stained VPA-treated HeLa cells.
(DOC)
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